NOVAST LABORATORIES LTD
SSZSE:30156918.42
CNY
+0.92
(+5.26%)
Return %
Stock
S&P 500
1Y
- -
13.14
3Y
- -
80.78
5Y
- -
67.74
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Guo Hua Zhang
- Full Time Employees
- 697
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Nantong China
- IPO Date
- Oct 15, 2026
- Website
- novast.cn
- Similar Companies
- Business
- Novast Laboratories Ltd is a pharmaceutical company that specializes in the research, development, manufacturing, and commercialization of complex oral prescription drug formulations, with specialized expertise in high-barrier controlled-release systems and low-dose drug delivery technologies. Founded in 2005 and headquartered in Nantong, Jiangsu Province, China, the company operates as a key operating entity within Novast Holdings Ltd, serving healthcare markets across the United States, China, and Canada. Novast Laboratories maintains research, development, and manufacturing facilities situated in the Nantong Comprehensive Bonded Zone that operate in strict compliance with current Good Manufacturing Practice (cGMP) regulations of the United States Food and Drug Administration (FDA) and the Chinese National Medical Products Administration (NMPA). The company operates across multiple therapeutic categories, including cardiovascular diseases, metabolic and endocrine disorders, women's reproductive health, and central nervous system disorders. The company's core product and service portfolio comprises: controlled-release and sustained-release solid oral dosage forms, including metoprolol succinate extended-release tablets for the treatment of hypertension, angina pectoris, and heart failure; nifedipine extended-release tablets for arterial hypertension and chronic stable angina; diltiazem hydrochloride extended-release capsules for hypertension and arrhythmia management; and conjugated estrogens extended-release tablets for hormone replacement therapy; low-dose and specialized pharmaceutical products, including levonorgestrel tablets and oral contraceptives engineered for microgram-level dosing uniformity and hormonal stabilization; central nervous system therapies, including oral solid formulations for the management of schizophrenia; and contract pharmaceutical services, including formulation development, analytical testing, contract research organization (CRO) services, contract development and manufacturing organization (CDMO) services, clinical trial material supply, and international regulatory filing support. In recent corporate developments, Novast Laboratories completed its initial public offering on the ChiNext board of the Shenzhen Stock Exchange in October 2026 under the ticker 301569, raising approximately RMB 936 million to finance industrialization production base expansions and advance complex formulation research and development projects. In late 2025, the company launched the first-to-market generic version of conjugated estrogens extended-release tablets in the United States following US FDA approval with a 180-day generic exclusivity period, overcoming longstanding formulation barriers to end an eight-decade originator monopoly and establishing a major driver of overseas revenue and profit margin growth. Novast Laboratories maintains a dual-market commercialization strategy, distributing commercial volumes in the United States through strategic partners such as Ingenus Pharmaceuticals under revenue- and profit-sharing models, while expanding its domestic presence in China through successful bids and renewals in the National Centralized Drug Procurement program for core products such as metoprolol succinate extended-release tablets. The company holds 48 US FDA-approved drug applications, with multiple products designated by the agency as Reference Standards for bioequivalence testing, and continues to expand its pipeline into metabolic indications, including extended-release metformin and empagliflozin-metformin combination therapies.